Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Which TKI Should Be Recommended as Initial Treatment for CML in Chronic Phase?

October 12, 2012
By Charles A. Schiffer, MD
News
Article
OncologyONCOLOGY Vol 26 No 10
Volume 26
Issue 10

Resistance due to new mutations in the genes coding for the targeted proteins, as well as to changes in other signaling pathways, often develops, and newer drugs and perhaps combination approaches may be needed.

The lessons learned from the specifically ”targeted” treatment of patients with chronic myeloid leukemia (CML) using imatinib (Gleevec) are now being applied with sometimes dramatic success in a variety of other tumors in which critical driving mutations have been identified, including some, such as malignant melanoma and lung cancer, that are notoriously resistant to other treatments. Sadly, but as might have been predicted from the experience in more advanced-stage CML, resistance due to new mutations in the genes coding for the targeted proteins, as well as to changes in other signaling pathways, often develops, and newer drugs and perhaps combination approaches may be needed.

The overall results with tyrosine kinase inhibitors (TKIs) in CML in chronic phase remain excellent, however, and Drs. Goldman and Marin nicely summarize the results of current treatments and the dilemmas posed by the availability of three (and perhaps soon four) alternatives to imatinib-although they do not actually tell us what they would recommend to the next newly diagnosed patient whom they will see in their practice. Some points of reference for my further discussion:

1. Approximately 60% of newly diagnosed CML patients will remain in complete cytogenetic remission and continuing on imatinib 5+ years after treatment is begun, with an extremely low rate of relapse if they continue to take the drug.[1] Some patients will have variably bothersome symptoms, particularly fatigue and muscle cramps, although serious late side effects have not occurred with now up to 12 years of follow-up.

2. With the recent US Food and Drug Administration (FDA) approval of bosutinib (Bosulif) for patients with CML who do not respond to or who are intolerant of imatinib, there are now three drugs available for second-line treatment. Approximately 40% to 50% of patients treated with these drugs will achieve complete cytogenetic responses, with occasional patients responding to an alternative tyrosine kinase inhibitor (TKI) as third-line therapy if particular BCR/ABL kinase mutations are present.[2-5] Responses have been higher in the patients who were intolerant of imatinib and seem to be durable. Of interest is that, at least in my experience, most patients who are switched report that they have fewer constitutional symptoms than they had with imatinib. Among the newer TKIs, the longest reported follow-up is with dasatinib (Sprycel), and although progression-free survival is ~ 60% at 6 years, only about 30% of the original cohort of patients are continuing to receive dasatinib.[6] Thus, there are still a significant number of chronic-phase patients with unsatisfactory outcomes using the treatment sequence of imatinib followed by an alternative TKI if needed, with poorer results in patients who present in advanced chronic or accelerated phases. We do not know whether the outcome would be better using the more potent TKIs as initial therapy. Randomized trials comparing imatinib to dasatinib or nilotinib (Tasigna) or bosutinib have shown very similar results, with molecularly deeper and more rapid responses using the newer drugs, although in some trials the differences became smaller with longer follow-up.[7-9] Again, as was noted above regarding the use of these drugs in the second-line setting, ~25% of patients were no longer receiving the second-generation drugs within 1 to 2 years of follow-up, because of either side effects or worsening disease. Unfortunately, as is common in pharmaceutical company–sponsored trials, there is less detailed follow-up of the patients who went “off study.” One could surmise that patients intolerant of treatment were switched to imatinib or dasatinib/nilotinib; it is not obvious how to manage patients whose disease progressed on the newer agents except for the use of experimental treatments or referral for allogeneic transplant.

The overall survival in chronic-phase patients in whom TKI therapy has “failed” remains around 60% to 70+%[6]-considerably higher than would have been expected in the pre-TKI era-and it is of interest to speculate that exposure to TKIs somehow slows the rate of acquisition of the additional mutations associated with blast crisis. Nonetheless, it is likely that the “clock is ticking” in patients without sustained complete cytogenetic responses.

It is not unusual in oncology (as in medicine generally) to have to make recommendations about treatment based on incomplete data and/or imperfect trials-or in the case of chronic diseases such as CML, on the basis of relatively short follow-up. Based on the consistency among the three randomized trials,[7-9] I generally recommend either dasatinib or nilotinib to newly diagnosed patients and certainly to all patients who present with more advanced chronic-phase disease as defined by Sokol risk group. The efficacy results do not favor one drug or the other; the choice is occasionally governed by the presence of pretreatment conditions that might favor one of the drugs over the others on account of their differing toxicity profiles. We have noted that some patients express a preference for the more convenient once-a-day dosing with dasatinib. One factor affecting treatment decisions, somewhat unique to the United States, is the variable and sometimes appreciable size of patient co-pays for outpatient anticancer drugs. If patients expect to have sizable out-of-pocket costs, I am comfortable with starting with imatinib and switching if necessary. Certainly, this will become an even more important societal issue when generic imatinib becomes available, with a presumed (and hopefully major) decrease in the cost of this agent. Hopefully, at that time, we will have more mature follow-up data from the randomized trials and perhaps better criteria for selection of patients who can do well on imatinib alone.

Financial Disclosure:Dr. Schiffer has received research funding from Novartis, Bristol-Myers Squibb, and Ariad; he has consulted for Novartis, Bristol-Myers Squibb, Ariad, Pfizer, and Teva.

References:

REFERENCES

1. Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-61.

2. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141-5.

3. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-41.

4. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, supoptimal response or intolerance to imatinib. Haematologica. 2010;95:232-40.

5. Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403-12.

6. Shah NP, Kantarjian H, Kim DW, et al. Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. ASCO Proceedings, Abstract 6506, 2012.

7. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123-9.

8. Saglio G, Kim DW, Issaragrisil S, et al; for the ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.

9. Cortes JE, Maru A, De Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia-BELA trial: 24-month follow-up. ASH Annual Meeting Abstracts. 2011;118:455.

Articles in this issue

Healthcare Financing and the Cost of Cancer Care
The Cost of Cancer Care: There Is More Than One Elephant in the Room
Targeted Therapy for Cancer: Asking the Right Questions
Improving Harmonious Precision
Sixty Is the New Forty-or Is It the Other Way Around?
Thymomas: A Continuing Challenge
Relative Roles of Targeted Therapies and Immunotherapies in Melanoma
Relative Roles of Targeted Therapies and Immunotherapies in Melanoma
Controversies in the Pathology of Thymoma Viewed Through the Prism of Evidence-Based Pathology
The Cost of Cancer Care: Part I
Bone-Modifying Agents as Adjuvant Therapy for Early-Stage Breast Cancer
Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I
Thymoma: Current Concepts
Thymoma: Current Concepts
Can Bone-Targeted Therapy Reduce Recurrence and Improve Survival in Early-Stage Breast Cancer?
Front-Line TKI Therapy for Chronic-Phase CML: the Luxury of Choice
Which TKI Should Be Recommended as Initial Treatment for CML in Chronic Phase?
Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

American Society for Transplantation and Cellular Therapy
June 25th 2025
Article

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.